Bristol-Myers Squibb Evolves R&D Strategy
Bristol-Myers Squibb is evolving its strategic focus in R&D to ensure continued leadership in delivering innovative medicines for patients with serious disease. The company will focus investment on priority areas such as immuno-oncology, delivering its late-stage pipeline across all its therapeutic areas and focusing discovery to explore disease areas of highest unmet medical need where the company can bring the greatest value. The evolved strategic focus in R&D will support and advance Bristol-Myers Squibb's overall BioPharma strategy, which remains unchanged.
"We are focusing our R&D organization on delivering the opportunities where the value is greatest to patients," said Francis Cuss, executive vice president and chief scientific officer, Bristol-Myers Squibb. "We have decided to shift R&D toward a more specialty BioPharma model that focuses on the areas of significant unmet medical need, driving near-term growth through our current late-stage portfolio and on ensuring the long-term growth of the company by evolving the disease areas and drug platforms on which we concentrate our research efforts."
Under this new strategic focus in R&D, Bristol-Myers Squibb will
• Continue to advance the lifecycle and late-stage pipeline, executing development, regulatory and commercial plans for the diabetes franchise, Eliquis® (apixaban), Sprycel® (dasatinib), Orencia® (abatacept), Erbitux® (cetuximab), Baraclude® (entecavir), Reyataz® (atazanavir sulfate)/Sustiva® (efavirenz), and hepatitis C.
• Increase investment in immuno-oncology, an area of significant opportunity, to realize the full potential of immunotherapy in certain cancers.
• Evolve the disease areas and drug platforms on which we concentrate our research efforts to drive growth for the company in 2020 and beyond by discontinuing broad based discovery work in hepatitis C, diabetes and neuroscience. The company will continue to focus on HIV, HBV, heart failure, oncology, immunoscience and fibrotic diseases.